Keynote 407: the combination of pembrolizumab and chemotherapy cracks the shell of squamous cell lung cancer.
作者信息
Viteri Santiago, Cabrera-Gálvez Carlos, Rosell Rafael
机构信息
Dr. Rosell Oncology Institute, Teknon Medical Center, Quironsalud Group, Barcelona, Spain.
Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain.
出版信息
Transl Lung Cancer Res. 2020 Jun;9(3):828-832. doi: 10.21037/tlcr-20-400.
Abstract
摘要
相似文献
1
Keynote 407: the combination of pembrolizumab and chemotherapy cracks the shell of squamous cell lung cancer.keynote 407：帕博利珠单抗与化疗联合疗法攻克鳞状细胞肺癌壁垒
Transl Lung Cancer Res. 2020 Jun;9(3):828-832. doi: 10.21037/tlcr-20-400.
2
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.帕博利珠单抗或安慰剂联合培美曲塞和铂类化疗用于未经治疗的转移性非鳞状非小细胞肺癌患者的疗效报告（KEYNOTE-189）：一项多中心、双盲、随机、安慰剂对照、III 期临床试验。
Lancet Oncol. 2020 Mar;21(3):387-397. doi: 10.1016/S1470-2045(19)30801-0. Epub 2020 Feb 6.
3
Pemetrexed maintenance with or without pembrolizumab in non-squamous non-small cell lung cancer: A cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBL.培美曲塞维持治疗联合或不联合帕博利珠单抗治疗非鳞状非小细胞肺癌：KEYNOTE-189 与 PARAMOUNT、PRONOUNCE、JVBL 试验的交叉比较。
Lung Cancer. 2021 Jan;151:25-29. doi: 10.1016/j.lungcan.2020.11.018. Epub 2020 Nov 20.
4
Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up.帕博利珠单抗联合化疗治疗肿瘤比例分数小于 1%的程序性死亡配体 1 阳性转移性非小细胞肺癌：五年随访后结局的汇总分析。
J Thorac Oncol. 2024 Aug;19(8):1228-1241. doi: 10.1016/j.jtho.2024.04.011. Epub 2024 Apr 18.
5
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.帕博利珠单抗单药治疗 PD-L1 阳性晚期非小细胞肺癌老年患者的安全性和有效性：来自 KEYNOTE-010、KEYNOTE-024 和 KEYNOTE-042 研究的汇总分析。
Lung Cancer. 2019 Sep;135:188-195. doi: 10.1016/j.lungcan.2019.07.004. Epub 2019 Jul 8.
6
Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407.帕博利珠单抗联合化疗治疗 KEYNOTE-407 研究中的日本转移性鳞状非小细胞肺癌患者
Cancer Sci. 2023 Aug;114(8):3330-3341. doi: 10.1111/cas.15816. Epub 2023 May 15.
7
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.一线帕博利珠单抗对比化疗用于转移性非小细胞肺癌：KEYNOTE-024 日本亚组。
Cancer Sci. 2020 Dec;111(12):4480-4489. doi: 10.1111/cas.14647. Epub 2020 Oct 16.
8
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407.帕博利珠单抗联合铂类化疗治疗 NSCLC 合并稳定脑转移患者的疗效：KEYNOTE-021、-189 和 -407 的汇总分析。
J Thorac Oncol. 2021 Nov;16(11):1883-1892. doi: 10.1016/j.jtho.2021.06.020. Epub 2021 Jul 12.
9
Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia.帕博利珠单抗对比化疗用于 KEYNOTE-181 亚洲人群随机对照试验中的食管鳞癌患者。
ESMO Open. 2022 Feb;7(1):100341. doi: 10.1016/j.esmoop.2021.100341. Epub 2021 Dec 29.
10
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.卡铂和培美曲塞联合或不联合帕博利珠单抗用于晚期非鳞状非小细胞肺癌：开放标签KEYNOTE-021研究的随机2期队列研究
Lancet Oncol. 2016 Nov;17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3. Epub 2016 Oct 10.
引用本文的文献
1
Treatment of MGMT promoter unmethylated glioblastoma with PD-1 inhibitor combined with anti-angiogenesis and epidermal growth factor receptor tyrosine kinase inhibitor: a case report.用PD-1抑制剂联合抗血管生成及表皮生长因子受体酪氨酸激酶抑制剂治疗O-6-甲基鸟嘌呤-DNA甲基转移酶启动子未甲基化的胶质母细胞瘤：1例报告
Ann Transl Med. 2021 Oct;9(19):1508. doi: 10.21037/atm-21-4625.
2
Messing Up the Cancer Stem Cell Chemoresistance Mechanisms Supported by Tumor Microenvironment.扰乱由肿瘤微环境支持的癌症干细胞化疗耐药机制。
Front Oncol. 2021 Jul 20;11:702642. doi: 10.3389/fonc.2021.702642. eCollection 2021.
3
Neoadjuvant programmed cell death protein 1 inhibitors combined with chemotherapy in resectable non-small cell lung cancer: an open-label, multicenter, single-arm study.新辅助程序性细胞死亡蛋白1抑制剂联合化疗用于可切除非小细胞肺癌：一项开放标签、多中心、单臂研究。
Transl Lung Cancer Res. 2021 Feb;10(2):1020-1028. doi: 10.21037/tlcr-21-130.
本文引用的文献
1
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.无驱动基因改变的 IV 期非小细胞肺癌的治疗：ASCO 和 OH（CCO）联合指南更新。
J Clin Oncol. 2020 May 10;38(14):1608-1632. doi: 10.1200/JCO.19.03022. Epub 2020 Jan 28.
2
Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC.帕博利珠单抗联合化疗联合 PD-L1 检测用于 NSCLC 一线治疗的成本效果分析。
Cancer Med. 2020 Mar;9(5):1683-1693. doi: 10.1002/cam4.2793. Epub 2020 Jan 16.
3
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer.非小细胞肺癌中肿瘤突变负荷定量的标准化及其与免疫检查点阻断反应的关联
JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00171. Epub 2019 Nov 12.
4
Tumor mutational burden in lung cancer: a systematic literature review.肺癌中的肿瘤突变负荷：一项系统文献综述
Oncotarget. 2019 Nov 12;10(61):6604-6622. doi: 10.18632/oncotarget.27287.
5
Significance of TIM3 expression in cancer: From biology to the clinic.TIM3 表达在癌症中的意义：从生物学到临床。
Semin Oncol. 2019 Aug-Oct;46(4-5):372-379. doi: 10.1053/j.seminoncol.2019.08.005. Epub 2019 Nov 6.
6
OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers.非小细胞肺癌中肿瘤浸润淋巴细胞的OX40和OX40L蛋白表达及其在临床结局中的作用以及与其他免疫生物标志物的关系
Transl Lung Cancer Res. 2019 Aug;8(4):352-366. doi: 10.21037/tlcr.2019.08.15.
7
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.一线帕博利珠单抗治疗 PD-L1 表达非常高的非小细胞肺癌患者的结局。
Ann Oncol. 2019 Oct 1;30(10):1653-1659. doi: 10.1093/annonc/mdz288.
8
Proteogenomic landscape of squamous cell lung cancer.鳞状细胞肺癌的蛋白质基因组景观。
Nat Commun. 2019 Aug 8;10(1):3578. doi: 10.1038/s41467-019-11452-x.
9
Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer.细胞毒化疗作为一种免疫刺激剂：从分子角度看待癌症的免疫升温。
Front Immunol. 2019 Jul 17;10:1654. doi: 10.3389/fimmu.2019.01654. eCollection 2019.
10
Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy.去除 N-连接糖基化可增强 PD-L1 的检测，并预测抗 PD-1/PD-L1 治疗效果。
Cancer Cell. 2019 Aug 12;36(2):168-178.e4. doi: 10.1016/j.ccell.2019.06.008. Epub 2019 Jul 18.
Zotero 插件